Related Experiment Video
Updated: Aug 14, 2025
11:12
Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
Published on: August 1, 2018
8.1K
[Clinically relevant molecular pathological diagnostics in breast cancer]
Fiona R Rodepeter1, Julia Teply-Szymanski1, Marcel Romey1
1Institut für Pathologie, Philipps-Universität Marburg und Universitätsklinikum Gießen und Marburg (UKGM), Baldingerstr. 1, 35043, Marburg, Deutschland.
Pathologie (Heidelberg, Germany)
|January 11, 2023
Summary
Advanced molecular analysis in breast cancer pathology identifies key predictive markers for targeted therapies. Comprehensive characterization, including next-generation sequencing (NGS), guides personalized treatment decisions, especially in advanced or relapsed disease.
Area of Science:
- Oncology
- Molecular Pathology
- Genomics
Context:
- Current breast cancer guidelines mandate advanced molecular analysis alongside immunohistochemistry.
- Predictive molecular markers are crucial for guiding targeted therapy decisions.
- Tumor stage influences the choice of molecular testing methods, including sequencing and immunohistochemistry.
Purpose:
- To outline the importance of comprehensive molecular characterization in breast cancer.
- To highlight specific molecular alterations (e.g., PIK3CA, BRCA1/2, NTRK fusions, microsatellite instability) relevant for targeted therapy.
- To emphasize the role of next-generation sequencing (NGS) panel diagnostics for identifying actionable mutations.
Summary:
- Advanced molecular profiling of breast tumors is essential for identifying targetable genetic alterations.
- Investigating mutations in PIK3CA, BRCA1/2, NTRK fusions, and microsatellite instability provides a basis for personalized treatment.
- Analysis of alterations in pathways like PI3K, ESR1, and ERBB2 is critical for managing resistant or relapsed breast cancer.
Impact:
- Comprehensive molecular characterization enables the identification of tumor drivers and personalized therapeutic strategies.
- NGS panel diagnostics offer a suitable approach for analyzing numerous molecular targets.
- Molecular-based treatment decisions, particularly for off-label therapies, require interdisciplinary discussion in a molecular tumor board.
